Flash Therapeutics will attend the ASGCT Annual Meeting, May 16-19, 2018 in Chicago, IL, USA.
Vectalys et FlashCell fusionnent pour créer Flash Therapeutics, une nouvelle entreprise de thérapie génique.
We are proud to announce that Vectalys has been awarded a Seal of Excellence certificate from the European commission as a result of its Horizon 2020 application.
Pascale Bouillé, CEO of Vectalys and president at FlashCell, was at the "Bioproduction des immunothérapies en France" conference at Biocitech Romainville on 09-26-2017 to talk about our new generat...
The FlashCell team looks forward to sharing its recent data about LentiFlash™ for genome-editing and immunotherapy approaches at the ESGCT 2017.
Vectalys is proud to launch FlashCell, a new gene therapy company specialized in the development of RNA carriers for therapeutic applications.
Learn more about FlashCell company on http://www.flash...